


FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. 024751-00000	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				DATE: August 10, 2001	
				U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.5) 09/890283	
INTERNATIONAL APPLICATION NO. PCT/CA00/00144		INTERNATIONAL FILING DATE 11 February 2000		PRIORITY DATE CLAIMED 11 February and 12 February 1999	
TITLE OF INVENTION: STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES					
APPLICANT(S) FOR DO/EO/US: Alex CIMPOIA, Lana JAMES, Romas KAZLAUSKAS					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures [35 U.S.C. 371(f)] at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper demand for International Preliminary Amendment was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English [35 U.S.C. 371(c)(2)].</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]</p> <p>a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].</p> <p>Items 11 - 16 below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: PCT/IPEA/408, PCT/IPEA/416, PCT/IPEA/409, PCT/ISA/220, PCT/ISA/210</p> <p><i>CL # 323463</i></p>					

U.S. APPL. NO. (IF KNOWN, SEE 37 C.F.R. 1.492) 09/890283	INTERNATIONAL APPLICATION NO. PCT/CA00/00144	ATTORNEY DOCKET NO. 024751-00000 DATE: August 10, 2001			
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee [37 C.F.R. 1.492(a)(1)-(5)]: Search Report has been prepared by the EPO or JPO.....\$860.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482).....\$690.00 No international preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but international search fee paid to USPTO [37 C.F.R. 1.445(a)(2)].....\$710.00 Neither international preliminary examination fee (37 C.F.R. 1.482) or international search fee [37 C.F.R. 1.445(a)(2)] paid to USPTO.....\$1,000.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 100.00		CALCULATIONS PTO USE ONLY <hr/>			
ENTER APPROPRIATE BASIC FEE AMOUNT = Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(e)].		\$ 860 \$ 00			
Claims	Number Filed	Number Extra	Rate		
Total Claims	13 - 20 =	00	X \$ 18.00	\$ 00	
Independent Claims	01 - 3 =	00	X \$ 80.00	\$ 00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$ 00	
TOTAL OF ABOVE CALCULATIONS =				\$ 860	
Reduction by one-half for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 C.F.R. 1.9, 1.27, 1.28).				\$ 00	
SUBTOTAL =				\$ 860	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(f)].				\$ 00	
TOTAL NATIONAL FEE =				\$ 860	
Fee for recording the enclosed assignment [37 C.F.R. 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				\$ 00	
TOTAL FEES ENCLOSED =				\$ 860	
				Amount to be refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> Check # _____ in the amount of \$ 860 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 01-2300 in the amount of \$ _____ to cover the above fee. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2300.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive [37 C.F.R. 1.137(a) or (b)] must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Arent Fox Kintner Plotkin & Kahn, PLLC 1050 Connecticut Avenue, N.W. Suite 600 Washington, D.C. 20036-5339 Tel: (202) 857-6000 Fax: (202) 638-4810					
				 Robert B. Murray Reg. No. 22,980	

STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUESFIELD OF THE INVENTION

The present invention relates generally to a novel method for the preparation of nucleoside analogues and their precursors and more particularly to a method of preparing a nucleoside analogue by the use of specific enzymes to stereoselectively produce dioxolane nucleoside analogues or their precursors.

BACKGROUND OF THE INVENTION

The pharmacological activity of pharmaceutical compounds (drugs) depend mainly on their interaction with biological matrices (drug targets), such as proteins (receptors and enzymes), nucleic acids (DNA and RNA) and biomembranes (phospholipids and glycolipids). All these drug targets have complex three-dimensional structures which are capable of binding specifically to the drug in only one of the many possible arrangements in the three-dimensional space. It is the three-dimensional structure of the drug target that in part, determines which of the potential drug is bound within its cavity and with what affinity.

The spatial arrangement of atoms in an asymmetric molecule is termed chirality. Chirality results in the creation of stereoisomers. Stereoisomers are compounds with identical chemical composition and atom connectivity (i.e. same constitution), but different arrangements of the atoms in space (i.e. different configurations). Stereoisomers are classified according to the number of

chiral centers in each molecule and the spatial arrangement of the chiral center.

Chiral centers of organic molecules include chiral carbon atoms which have four different substituents connected thereto and arranged in a generally tetrahedral configuration. Another type of chiral center is a chiral plane oriented along a rigid C=C bond that has at least two different substituents connected to the remaining four bond positions in that arrangement.

The chirality of molecules that are the subject of the present application refer to chirality created by chiral atoms and not chiral bonds. The following discussions will be limited to chirality created at one or more chiral carbon atoms which have four different substituents bound to each of the four different binding sites of the carbon.

When a molecule has a single chiral carbon, there are two stereoisomers that are mirror images of each other. This pair of isomers is termed enantiomers or an enantiomeric pair. When there are two chiral carbon atoms, there are four stereoisomers and two pairs of mirror images or enantiomers. A stereoisomer which is not a mirror image of another stereoisomer is a diastereoisomer.

One type of stereochemical distinction relates to cyclic sugars or analogues of cyclic sugars. Cyclic sugars can be designated as a particular anomer depending upon the stereochemical configuration.

The term "anomer" designates the spatial arrangement of cyclic sugars or analogues or derivatives thereof that

have two chiral centers in a five or six member ring. The anomeric designation defines the relative configuration of the two chiral centers relative to a hypothetical plane defined by the ring. The chiral centers typically have two substituents outside the ring. One substituent is a H. The other substituent is a larger moiety such as a hydroxyl, methoxyl, purine or pyrimidine base, carboxyl, etc.

When the two larger constituents on each chiral center are on the same side of the plane in the ring, they are defined as a β -anomer (cis-isomer). When two larger moieties are on opposite sides of the plane in the ring, they are defined as the α -anomer (trans-isomer). An anomer is a type of diastereoisomer.


Because chirality may affect biological activity or toxicity, it is important from the point of view of drug development to evaluate the physiological effect of each isomer. Frequently, one stereoisomer is considerably more active than the other. In other situations, the non-active isomer may inhibit the activity of the more active form. In some instances, the less preferred stereoisomer may be equally potent but have greater toxicity than the preferred stereoisomer. In each of these instances, the therapeutic effect of a drug can be increased if the single most preferred stereoisomer is administered in higher purity.

The current trend in the drug markets reflects a greater use of single stereoisomer drugs. The sales of single stereoisomer drugs have increased considerably. In 1995, sales of single stereoisomer drugs reached \$61 billion

worldwide. In the year 2000, the annual worldwide sales are expected to reach \$90 billion.

An important class of pharmacological agents relate to 3'-oxa-substituted 2',3'-dideoxynucleoside analogues ("dioxolane nucleoside analogues"). These compounds have two chiral centers corresponding to the substituted carbons 2 and 4 of the dioxolane ring (C2 and C4 respectively). Thus each compound can exist as four different stereoisomers depending on the position of both substituents with respect to the dioxolane ring.

The stereoisomers of a dioxolane nucleoside analogue are represented by the following diagrams where the letter B represents a purine or pyrimidine base or an analogue or derivative of a purine or pyrimidine base as defined herewith.



For the purpose of consistency, the same stereochemical designation is used when the methyloxyl moiety or the base moiety is replaced with another substituent group.

The C2 carbon in each of the above formula is the carbon atom in the ring that connects the methyloxy group to the dioxolane ring. The C4 carbon is the carbon atom in each of the above formula that connects the base (B) substituent to the dioxolane ring.

The four stereoisomers represented above correspond to two pairs of enantiomers. The β -anomers represent one set of enantiomers, the β -L enantiomer and the β -D enantiomer. The α -anomers represent the other set of enantiomers, the α -L enantiomer and the α -D enantiomer.

Compounds with D-configuration have an outward directed methyloxy group when the ring is oriented in the plane of the page with the oxygen in the first position (O3) at the top of the page with the carbon in the two position (C2) on the left side as illustrated above. This is also represented by the designation (2R). Compounds having an L-configuration has inward directed methyloxy group when the ring is oriented in the plane of the page with the O3 oxygen at the top of the page with the C2 carbon on the left side as illustrated above. This is also represented by the designation (2S).

A variety of dioxolane nucleoside analogues have been identified to have antiviral and anticancer activity. For example, 9-(β -D-2-hydroxymethyl-1,3-dioxolan-4-yl)-2-aminopurine (β -D-DAPD) and its metabolite 9-(β -D-2-hydroxymethyl-1,3-dioxolan-4-yl)-guanine (β -D-DXG) have been reported to have potent and selective activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) (Rajagopalan et al., Antiviral Chem. Chemother., 1996, 7(2), 65-70) Similarly, 1-(β -L-2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine (Dioxolane-T) (Norbeck et al., Tetrahedron Lett., 1989, 30, 6263-66) possess anti-HIV and anti-HBV activity. 1-(β -L-2-hydroxymethyl-1,3-dioxolan-4-yl)-cytidine (β -L-OddC) (Bednarski et al., Bioorg. Med. Chem. Lett., 1994, 4,

2667-72) was discovered to have potent anti-tumor activity towards human prostate as well as renal carcinoma (Kadhim et al., Can. Cancer Res., 57(21),4803-10, 1997). β -L-OddC is the first nucleoside analogue with an L-configuration shown to have anticancer activity. Since stereoisomers of dioxolane nucleosides usually have different biological activities and toxicity, obtaining the pure therapeutically active isomer becomes crucial.

Chiral synthetic methods have improved over the past several years with respect to synthetic techniques that result in single stereoisomer compounds. However, there is a present need to find novel synthetic methods which can be widely used to form a particular stereoisomer with greater efficiency and purity.


For example, for many years a person of ordinary skill in the art could use enzymes to separate enantiomers of dioxolane compounds. However, it is not known in the art how to produce a dioxolane nucleoside analogue using a step of separating an anomeric mixture of certain dioxolane precursors using enzymes to produce a stereochemically pure end product with greater efficiency and purity.

Because stereochemically pure dioxolane nucleosides are an important class of compounds due to their known antiviral and anticancer activity, there is a need for other inexpensive and efficient stereoselective methods for their preparation. The present invention satisfies this and other needs.

SUMMARY OF THE INVENTION

The present invention provides a novel process for making dioxolane nucleoside analogues with a high degree of steric purity, greater efficiency and higher yields.

Specifically, the present invention provides a process for making dioxolane nucleoside analogues with a high degree of steric purity which includes the use of certain hydrolytic enzymes for separating β and α anomers from an anomeric mixture represented by the following formula A or formula B:



In the above formula, W is benzyl or benzoyl; R_1 is selected from the group consisting of C_{1-6} alkyl and C_{6-15} aryl.

The process involves the step of hydrolyzing the mixture of compounds represented by formula A and formula B with an enzyme selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*, protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-05, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species

type B, lipase from *Pseudomonas cepacia* and bacterial proteinase. The process stereoselectively hydrolyses predominantly one anomer to form a product where R_1 of formula A and formula B is replaced with H. The other anomer remains substantially unhydrolysed. The process also comprises separating the hydrolyzed product from unhydrolysed starting material.

The process of one embodiment further includes the step of stereoselectively replacing the functional group at the C4 position of the dioxolane (e.g. $COOR_1$) with a purinyl, pyrimidinyl or analogue or derivative thereof to produce a dioxolane nucleoside analogue that has a high degree of steric purity.

According to one embodiment of the invention, the step of hydrolyzing results in a starting material having an anomeric purity of at least 80%. According to another embodiment, the step of hydrolyzing results in a starting material having an anomeric purity of at least 90%. In yet another embodiment, the step of hydrolyzing results in a starting material having an anomeric purity of at least 95%. In an additional embodiment, the step of hydrolyzing results in a starting material having an anomeric purity of at least 98%.

According to one embodiment of the invention, the step of hydrolyzing results in a product having an anomeric purity of at least 80%. According to another embodiment, the step of hydrolyzing results in a product having an anomeric purity of at least 90%. In yet another embodiment, the step of hydrolyzing results in a product having an anomeric purity of at least 95%. In an


additional embodiment, the step of hydrolyzing results in a product having an anomeric purity of at least 98%.

In one embodiment of the present invention, W of formula A or formula B is benzyl and the enzyme is selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*. In another embodiment, the enzyme is α -chymotrypsin. In yet another embodiment, the enzyme is bovine pancreatic protease.

In one embodiment of the present invention, W of formula A and formula B is benzoyl and the enzyme is selected from the group consisting of protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, subtilisin from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-05, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, bacterial proteinase, lipase from *Pseudomonas cepacia*. In another embodiment, the enzyme is selected from the group consisting of *Aspergillus oryzae* protease, proteinase from *Bacillus licheniformis*, subtilisin from *Bacillus licheniformis*, protease from *Streptomyces griseus*, pronase protease from *Streptomyces griseus*, and lipase from *Rhizopus arrhizus*. In yet another embodiment, the enzyme is selected from the group comprising *Aspergillus oryzae* and proteinase from *Bacillus licheniformis*.

In one embodiment, the β -anomer is the predominant product. In another embodiment, the α -anomer is the predominant product. In yet another embodiment, the β -L-enantiomer is the predominant product. In an additional embodiment, the β -D-enantiomer is the predominant product. In yet another embodiment, the α -L-enantiomer is the predominant product. In an additional embodiment, the α -D-enantiomer is the predominant product.


In one embodiment, the invention is a process for stereoselectively preparing a dioxolane nucleoside analogue by separating β and α -anomers from an anomeric mixture represented by formula A or formula B according to one of the above embodiments. The process further includes the step of stereoselectively replacing the functional group at the C4 position (COOR_1) with a purinyl or pyrimidinyl or analogue or derivative selected from the group consisting of:



In this embodiment, R_2 , R_9 and R_{11} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} acyl and $R_8C(O)$ wherein R_8 is hydrogen or C_{1-6}


alkyl. Additionally, R_3 , R_4 and R_{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, bromine, chlorine, fluorine, iodine and CF_3 ; and R_5 , R_6 and R_7 are each independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, amino, hydroxyl and C_{3-6} cycloalkylamino. The process results in the production of a stereochemical isomer of the dioxolane nucleoside analogue.

According to one embodiment, the process further includes the step of stereoselectively replacing the functional group at the C4 position ($COOR_1$) with a purinyl or pyrimidinyl or derivative selected from the group consisting of:



In this embodiment, R_2 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} acyl and $R_8C(O)$ wherein R_8 is hydrogen or C_{1-6} alkyl. Additionally, R_3 and R_4 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, bromine, chlorine, fluorine, iodine and CF_3 ; and R_5 , R_6 and R_7 are each independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, amino, hydroxyl and C_{3-6} cycloalkylamino. The process results in the production of a stereochemical isomer of a dioxolane nucleoside analogue.


In another embodiment, the process further includes the step of stereoselectively replacing the functional group at the C4 position (COOR₁) with a pyrimidinyl or analogue or derivative selected from the group consisting of:



In this embodiment, R_9 and R_{11} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} acyl and $R_8C(O)$. Additionally, R_{10} is selected from the group consisting of hydrogen, C_{1-6} alkyl, bromine, chlorine, fluorine, iodine and CF_3 . The process results in the production of a stereochemical isomer of a dioxolane nucleoside analogue.

In another embodiment, the process comprises stereoselectively preparing a dioxolane nucleoside analogue by separating β and α anomers from an anomeric mixture represented by formula A or formula B according to one of the above embodiments and further comprises stereoselectively replacing the functional group at the

C4 position (COOR₁) with a moiety selected from the group consisting of:




In another embodiment of the present invention, the process comprises making a dioxolane nucleoside analogue by separating a compound according to formula A or formula B. According to this embodiment, the process includes stereoselectively replacing the R group with a purinyl or pyrimidinyl moiety or analogue or derivative thereof by acylating the second mixture to produce an acylated second mixture. This embodiment also includes the step of glycosylating the acetylated second mixture with a purine or pyrimidine base or analogue or derivative thereof and a Lewis Acid to produce a dioxolane nucleoside analogue.

DETAILED DESCRIPTION OF THE INVENTION


The present invention involves a high yield process of separating β and α anomers from an anomeric mixture of dioxolane nucleoside analogue precursors which provides higher yield and greater efficiency. In one embodiment, this method is used in the production of dioxolane nucleoside analogues having a high degree of anomeric purity at lower cost. Additionally, another aspect of the present invention involves synthesizing starting material having a higher degree of anomeric purity.

The present invention provides a process of preparing dioxolane nucleoside analogues having a predominant β -L-configuration using enzymes, namely hydrolases. The procedure improves overall yield and has relatively few steps, thereby improving overall efficiency. The process involves the following steps.

A mixture of anomers represented by formula A or formula B is obtained as described herein in Scheme 1.




(A)




(B)

In the above formula, W is benzyl or benzoyl, and R₁ is selected from the group consisting of H, C₁₋₆ alkyl and C₆₋₁₅ aryl. The mixture is hydrolyzed with an enzyme selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine

pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*, protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-05, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, lipase from *Pseudomonas cepacia* and bacterial proteinase. The hydrolyzing step stereoselectively hydrolyzes the α -anomer of the mixture of either formula A or formula B. The result is an unhydrolysed β -anomer. The α -anomer can be separated easily from the β -anomer. If an anomeric mixture of the compound of formula A is selected, the result is the production of the compound of formula C and formula D:




(C)




(D)

If an anomeric mixture of the compound of formula B is selected, the result is the production of the compound of formula E and formula F:



(E)



(F)


The mixture (C)/(D) or (E)/(F) is then subjected to oxidative decarboxylation which replaces the R_1 group with an acyl moiety. It is then glycosylated with a purine or pyrimidine base or analogue or derivative thereof in the

presence of a Lewis Acid. The final step produces a dioxolane nucleoside analogue in the β -L configuration for the mixture (C)/(D) and a dioxolane nucleoside analogue in the β -D configuration for the mixture (E)/(F).

At the outset, the following definitions have been provided as reference. Except as specifically stated otherwise, the definitions below shall determine the meaning throughout the specification.

"Nucleoside" is defined as any compound which consists of a purine or pyrimidine base, linked to a pentose sugar.

"Dioxolane nucleoside analogue" is defined as any compound containing a dioxolane ring as defined hereinafter linked to a purine or pyrimidine base or analogue or derivative thereof. A "dioxolane ring" is any substituted or unsubstituted five member monocyclic ring that has an oxygen in the 1 and 3 positions of the ring as illustrated below:



"Purine or pyrimidine base" is defined as the naturally occurring purine or pyrimidine bases adenine, guanine, cytosine, thymine and uracil. A purine or pyrimidine that is a moiety is a purinyl or pyrimidinyl, respectively.


"Alkyl" is defined as a substituted or unsubstituted, saturated or unsaturated, straight chain, branched chain or carbocyclic moiety, wherein the straight chain,

branched chain or carbocyclic moiety can be optionally interrupted by one or more heteroatoms (such as oxygen, nitrogen or sulfur). A substituted alkyl is substituted with a halogen (F, Cl, Br, I), hydroxyl, amino or C₆₋₂₀ aryl.

"Aryl" is defined as a carbocyclic moiety which can be optionally substituted or interrupted by one heteroatom (such as oxygen, nitrogen or sulfur) and containing at least one benzenoid-type ring (such as phenyl and naphthyl).

"Carbocyclic moiety" is defined as a substituted or unsubstituted, saturated or unsaturated, C₃₋₆ cycloalkyl wherein a substituted cycloalkyl is substituted with a C₁₋₆ alkyl, halogen (i.e. F, Cl, Br, I), amino, carbonyl (i.e. COOH), or NO₂.

A "derivative" of a purine or pyrimidine base refers to one of the following structures:



wherein one or more of the pyrimidine H are substituted with substituents that are known in the art. In the above illustration, the bonds represented by a broken line are optional and are present only in cases which require the bond to complete the valence of the ring atom. Substituents bound to the ring members by a

single bond include but are not limited to halogen such as F, Cl, Br, I; an alkyl such as lower alkyls; aryl; cyano carbamoyl; amino including primary, secondary and tertiary amino; and hydroxyl groups. Substituents bound to the carbon ring atoms by a double bond include but are not limited to a =O to form a carbonyl moiety in the ring. It is understood that when the ring is aromatic, some of the substitutions may form tautomers. The definition shall include such tautomers.

"Analogue" of a purine or pyrimidine base refers to any derivative of purine or pyrimidine bases that is further modified by substituting one or more carbon in the ring structure with a nitrogen.

"Stereoselective enzymes" are defined as enzymes which participate as catalysts in reactions that selectively yield one specific stereoisomer over other stereoisomers.

"Anomeric purity" is defined as the amount of a particular anomer of a compound divided by the total amount of all anomers of that compound present in the mixture multiplied by 100%.

"Alkoxy" is defined as an alkyl group, wherein the alkyl group is covalently bonded to an adjacent element through an oxygen atom (such as methoxy and ethoxy).

"Alkoxy carbonyl", is defined as an alkoxy group attached to the adjacent group of a carbonyl.

"Acyl" is defined as a radical derived from a carboxylic acid, substituted (by a halogen, C₆₋₂₀ aryl or C₁₋₆ alkyl) or unsubstituted by replacement of the -OH group. Like


the acid to which it is related, an acyl radical may be aliphatic or aromatic, substituted (by halogen, C₁₋₆ alkoxyalkyl, nitro or O₂) or unsubstituted, and whatever the structure of the rest of the molecule may be, the properties of the functional group remain essentially the same (such as acetyl, propionyl, isobutanoyl, pivaloyl, hexanoyl, trifluoroacetyl, chloroacetyl and cyclohexanoyl).

"Alkoxyalkyl" is defined as an alkoxy group attached to the adjacent group by an alkyl group (such as methoxymethyl).

"Acyloxy" is defined as an acyl group attached to the adjacent group by an oxygen atom.

"Oxo" is defined as a =O substituent bonded to a carbon atom.

As noted above, one embodiment of the present invention is a process for separating β and α anomers from an anomeric mixture represented by the following formula A or formula B:




wherein W is benzyl or benzoyl and R₁ is selected from the group consisting of C₁₋₆ alkyl and C₆₋₁₅ aryl.

In one embodiment, the process stereoselectively hydrolyses predominantly the α -anomer to form a product

where R_1 of formula A and formula B is replaced with H. The β -anomer remains substantially unhydrolyzed. The process also comprises separating the hydrolyzed product from unhydrolyzed starting material.

The process of making a β -L dioxolane nucleoside analogue begins with the preparation of starting materials. Scheme 1 depicts the manufacture of a mixture that includes formula A or B.

Scheme 1



An oxyacetaldehyde represented by formula 1A (wherein W is benzyl or benzoyl) is reacted with 1,3-dioxolane-4-(4R)carboxylic acid-2,2-dimethyl-methyl ester (formula 1B) in approximately equimolar proportions. The dioxolane of formula 1B has a chiral center at the C4 carbon. The reaction occurs in a toluene solvent. The mixture is heated to 58°C. The catalyst, PTSA, is added. The mixture is heated to a temperature between 64-67°C. A vacuum is applied at 70 kPa, and the reaction proceeds for 40 minutes. Traces of solvent are then removed by high vacuum. The catalyst is removed by filtration using a 1:1 ratio of Hexane:EtOAc as an eluent. In one embodiment, the preferred filter is a silica gel pad.

The resulting product is a crude oil containing a mixture of the compounds of formula 1C and 1D, wherein the ratio is 2:1 of (1C:1D) respectively.

It can be appreciated by a person of skill in the art that the reaction conditions can be adjusted to optimize the purity of the stereoisomers. In one embodiment of the present invention, the reaction of the compound of formula 1A with the compound of formula 1B is done in the presence of catalyst in an amount between about 1.0 wt% and 10.0 wt% of the starting material. In another embodiment the amount of catalyst is between about 2.5 wt% and about 5.5 wt% of the starting materials. In yet another embodiment, the amount of catalyst is between about 3.0 wt% and about 5.0 wt%. In still another embodiment, the amount of catalyst is between about 3.5% and about 5.5%. In another embodiment, the amount of catalyst is between about 2.5 wt% and about 7.5 wt%. In another embodiment the amount of catalyst is about 5.0 wt%.


In an embodiment of the present invention, the reaction of the compound of formula 1A with the compound of formula 1B is done at a temperature ranging from about 40°C to about 80°C. In another embodiment of the present invention, the temperature ranges from about 50°C to about 75°C. In still another embodiment, the temperature ranges from about 60°C to about 70°C. In an additional embodiment, the temperature ranges from about 65°C to about 79°C.

In an embodiment of the present invention, the reaction time between the compound of formula 1A and the compound of formula 1B corresponds to a period ranging from about

30 minutes to about 2 hours. In yet another embodiment, the period ranges from about 30 minutes to about 1 hour. In still another embodiment, the period ranges from about 30 minutes to about 50 minutes.

It will be appreciated by a person of ordinary skill in the art that the C4 carbon is chiral. Because this carbon is not involved in the reaction, the chirality is preserved at that carbon. A starting material can be selected to have a (4S) or (4R) stereochemistry.

According to one embodiment, it is preferable that the resulting product is an anomeric mixture favoring the β -L configuration over the α -L configuration. To achieve such a result, the starting material represented by formula 1B (4S) is selected and shown below:




Formula 1B (4S)

The reaction proceeds according to the principles described above. The resulting product, according to one embodiment, will have an anomeric purity of the β -L anomer over the α -L anomer of greater than 55%, preferably 60% and more preferably 65%.

According to one embodiment, the present invention is a method of separating β -anomers from α -anomers according to the following Scheme 2:

Scheme 2



According to one embodiment, a mixture of anomers is obtained as represented by formula 2A or formula 2B. A mixture represented by formula 2A or formula 2B can be obtained according to the reaction described above or according to any method known in the art.

The reaction is prepared as follows: A portion of the material represented by formula 2A and formula 2B is weighed into a reaction vessel. For a small scale reaction, about 0.001 mmol of the mixture of formula 2A and formula 2B is added to about 46 mL of a 5 mmol solution of BES buffer (for a final concentration of

about 2 mM in substrate). For a preparative scale reaction, about 0.8 mmol of the mixture is added to about 10 mL of buffer (for a final concentration of about 80 mM in substrate). The pH of the buffer, according to one embodiment, should be between 7.0 and 7.5 and preferably 7.2.

The enzyme is selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*, protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-5, pronase, protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, lipase from *Pseudomonas cepacia* and bacterial proteinase.

The commercial sources of the enzymes are readily available to a person of ordinary skill in the art. Particularly, some of the materials can be obtained from the following sources: Bovine cholesterol esterase was purchased from Genzyme (Cambridge, MA); ESL-001-02 from Diversa Corp. (San Diego, CA); Horse liver esterase and subtilisin from *Bacillus licheniformis* from Fluka Chemie (Oakville, ON); Bovine pancreas protease type 1, α -chymotrypsin and *Streptomyces caespitosus* from Sigma-Aldrich (Oakville, ON).

In another embodiment, the enzyme is selected from the group consisting of protease from *Aspergillus oryzae*,

proteinase from *Bacillus licheniformis*, subtilisin from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-005, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, bacterial proteinase and lipase from *Pseudomonas cepacia*. The selection of one of these enzymes is preferred according to this embodiment when the oxyacetaldehyde represented by the compound of formula 1A in Scheme 1 is selected to be benzoyloxyacetaldehyde.

According to another embodiment of the invention, the oxyacetaldehyde represented by the compound of formula 1A is benzoyloxyacetaldehyde. According to this embodiment, the enzyme is selected from the group consisting of protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, subtilisin from *Bacillus licheniformis*, pronase protease from *Streptomyces griseus*, and lipase from *Rhizopus arrhizus*. In yet another embodiment, the enzyme is selected from the group consisting of protease from *Aspergillus oryzae* and proteinase from *Bacillus licheniformis*.

In yet another embodiment, the enzyme is selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus* and subtilisin from *Bacillus licheniformis*. The selection of one of these enzymes is preferred according to this embodiment when the oxyacetaldehyde represented by the compound of formula 1A is benzoyloxyacetaldehyde.

The stereospecific enzyme selected is then added to begin

the hydrolysis reaction. The enzymatic reaction hydrolyzes primarily the α -anomer by replacing the R_1 group of the α -anomer of the compound of formula 2B with H to form the compound of formula 2C. The amount of the enzyme added can be determined according to principles known by any person of ordinary skill in the art.

According to another embodiment, about 500 μ L was added to begin the reaction. The rate and degree of hydrolysis was monitored by a pH-stat according to principles known in the art. As the compound of formula 2B is hydrolyzed, the pH of the mixture decreases. Thus, the change in pH as monitored by a pH stat corresponds to the completeness of the reaction.

If the reaction time is allowed to proceed longer than the optimal reaction time, the β -anomer may be converted resulting in lower anomeric purity of the final product. If the reaction time is too short, less than optimal amount of the α -anomer is converted resulting in a lower anomeric purity of the remaining unhydrolyzed reactant. According to one embodiment, the reaction is allowed to proceed until 43% completion. It will be appreciated by a person of ordinary skill in the art that the exact degree of completion may change depending upon the reactant used, the enzyme used and other principles known to a person of ordinary skill in the art.

As noted, the ester starting material is separated from the hydrolyzed acid product when the desired endpoint is reached. The ester starting material and the hydrolysed product are separated by increasing the pH of the solution to more than pH 7.0 with bicarbonate solution and extracting with ethyl acetate (for example, 3 x 20

mL). The unhydrolyzed starting material is extracted in the ethyl acetate and the hydrolyzed product remains in salt form in the aqueous solution. The pH of the solution is then adjusted to pH 2. The hydrolyzed product is further extracted with ethyl acetate (for example, 3 x 20 mL). The reactants and the products are dried with MgSO_4 , filtered and concentrated in-vacuo.

Alternatively, the unhydrolyzed product can be hydrolyzed by procedures known in the art such as reaction with LiOH followed by acidification.


Because of the enzyme selectivity, the anomeric purity of the hydrolyzed and separated β -anomer is considerable. Furthermore, the anomeric purity of the unhydrolyzed and separated α -anomer is also considerable. In one embodiment, the anomeric purity of the respective separated α -anomer and/or the β -anomer is greater than 80%. In another embodiment, the anomeric purity of the respective separated α -anomer and/or the β -anomer is greater than 90%. In another embodiment, the anomeric purity of the respective separated α -anomer and/or the β -anomer is greater than 95%. In another embodiment, the anomeric purity of the respective separated α -anomer and/or the β -anomer is greater than 98%.

In another embodiment, the procedure of Scheme 2 is followed except the anomeric mixture represented by formula 2A or 2B is replaced with an anomeric mixture represented by formula 2D and 2E, respectively.

WO[C@H]1O[C@@H](C(=O)OR)[C@H](O)[C@H]1O


Formula 2E

According to this embodiment the α -anomer represented by formula 2E is hydrolyzed. The result is the separation of the hydrolyzed α -anomer represented by formula 2F from the unhydrolyzed β -anomer represented by formula 2D.



Formula 2F

In another embodiment, the procedure of Scheme 2 is followed except a mixture represented by formula 2A and 2B is replaced with a mixture of four stereoisomers represented by formula 2G.



Formula 2G

According to this embodiment, the α -anomer containing both D and L enantiomers is hydrolyzed. The result is the separation of the hydrolyzed α -anomer containing both D and L enantiomers from the unhydrolyzed β -anomer containing both D and L enantiomers.

After hydrolysis, purification and oxidative decarboxylation, the resulting dioxolane ring can be linked with a purine or pyrimidine base or analogue or derivative. There are several examples known by skilled artisan on how to link a purine or pyrimidine base or analogue or derivative to the dioxolane ring. For example, PCT Publ. No. WO/97/21706 by Mansour et al. describes one method of stereoselectively attaching the purine or pyrimidine base or analogue or derivative to a dioxolane ring. WO/97/21706 is incorporated herein fully by reference.

According to the process disclosed in WO/97/21706 the starting material is an acylated dioxolane ring. The starting material of the procedure disclosed in WO/97/21706 can be obtained by oxidative decarboxylation of a product of Scheme 2 discussed above. Oxidative decarboxylation destroys the stereochemistry of the C4 carbon while preserving the stereochemistry of the C2 carbon.

As noted, the oxidative decarboxylation step occurs after the hydrolysis step of Scheme 2. A compound having the desired stereochemistry on the C2 carbon is selected. For each mmol of compound that is processed, it is dissolved in between about 2.5 and about 4.0 mL of acetonitrile. In another embodiment, between about 3.0 and about 3.5 mL of acetonitrile was added for each mmol of compound. In yet another embodiment, between about 3.3 and about 3.4 mL of acetonitrile was added for each mmol of compound.

For each mmol of compound, between about 0.08 and about 0.12 mL of pyridine was added. In another embodiment,


between about 0.09 and about 0.11 mL of pyridine was added for each mmol of compound. In yet another embodiment, approximately 0.1 mL of pyridine was added for each mmol of compound.

To this mixture, between 1.1 and 1.5 mmoles of $\text{Pb}(\text{OAc})_4$ was added for each mmol of compound. In another embodiment, between about 1.2 mmoles and about 1.4 mmoles of $\text{Pb}(\text{OAc})_4$ is added for each mmol of compound. In yet another embodiment, about 1.3 mmoles of $\text{Pb}(\text{OAc})_4$ is added for each mmol of compound.

Thereafter, the mixture was stirred for 18 hours at room temperature. Then, the mixture was poured into a saturated solution of NaHCO_3 . Between approximately 2.0 and 3.0 mL of NaHCO_3 were used for each mmol of compound. In one embodiment, between about 2.5 mL and about 2.7 mL, and more preferably about 2.6 mL of NaHCO_3 was used for each mmol of compound. The solution was then stirred for an additional 30 minutes. The organic layer was separated from the aqueous layer by four extractions of ethyl acetate. Extracts were combined, dried on anhydrous Na_2SO_4 and evaporated under a vacuum. Optionally, the crude can be further purified by chromatography on silica gel using a gradient of 0-15% ethyl acetate in hexane.

In one embodiment of the present invention, the oxidative decarboxylation step is followed by glycosylation. The glycosylation is represented by the following Scheme 3.

SCHEME 3



The first step in the glycosylation procedure is to obtain a compound with the desired stereospecificity at the C2 carbon. According to one embodiment, a compound having an S stereochemistry at the C2 carbon, as represented by the compound of formula 3A is preferred. The result is that a higher ratio of the β -L anomer is in the product 3C. According to another embodiment, compound having an R stereochemistry at the C2 carbon is preferred. The result is a product that has a higher ratio of the β -D anomer in the final product.


The compound of formula 3A is reacted with an iodosilane to produce the compound of formula 3B. In one embodiment, the iodosilane is iodotrimethylsilane.

In another embodiment, the iodosilane is diiodosilane. Important to the reaction is that it occurs at low temperatures. According to one embodiment, the temperature is preferably between 0 °C and -78°C prior to

glycosylation with silylated pyrimidine or purine base or analogue or derivative thereof.

The iodo intermediate represented by formula 3B is then dissolved in dichloromethane and is cooled down to between 0° C and -78° C. A purine or pyrimidine base or analogue or derivative thereof is then selected.


According to one embodiment, the purine or pyrimidine base or analogue or derivative thereof is selected from the following group:



Wherein:


R₂, R₉ and R₁₁ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ acyl and R₈C(O) wherein R₈ is hydrogen or C₁₋₆ alkyl;
 R₃, R₄ and R₁₀ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, bromine, chlorine, fluorine, iodine and CF₃; and
 R₅, R₆ and R₇ are each independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, amino, hydroxyl and C₃₋₆ cycloalkylamino.

According to one embodiment, the purine or pyrimidine base or derivative is selected from the group consisting of:



In this embodiment, R_2 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} acyl and $R_8C(O)$ wherein R_8 is hydrogen or C_{1-6} alkyl. Additionally, R_3 and R_4 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, bromine, chlorine, fluorine, iodine and CF_3 ; and R_5 , R_6 and R_7 are each independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, amino, hydroxyl and C_{3-6} cycloalkylamino.

In another embodiment, the purine or pyrimidine base or analogue or derivative thereof is selected from the group consisting of:



In this embodiment, R_9 and R_{11} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} acyl and $R_8C(O)$. Additionally, R_{10} is selected from the

group consisting of hydrogen, C₁₋₆ alkyl, bromine, chlorine, fluorine, iodine and CF₃.

The purine or pyrimidine or analogue or derivative thereof is persylated by a sulating agent and ammonium sulphate followed by evaporation of HMDS to form a persylated purine or pyrimidine base or analogue or derivative thereof herein referred to as the persylated base and designated as P in Scheme 3. According to one embodiment, the sulating agent is selected from the group consisting of 1,1,1,3,3,3-hexamethyldisilazane, trimethylsilyl triflate, t-butyldimethylsilyl triflate or trimethylsilyl chloride. In one embodiment, the sulating agent is 1,1,1,3,3,3-hexamethyldisilazane.

The persylated base P was dissolved in 30 mL of dichloromethane and was added to the iodo intermediate represented by formula 3B. The reaction mixture was maintained at between 0 and -78°C for 1.5 hours then poured onto aqueous sodium bicarbonate and extracted with dichloromethane (2x25 mL). The organic phase was dried over sodium sulphate to obtain the compound of formula 3C. As used in Scheme 3, the B represents a moiety of the purine or pyrimidine base or analogue or derivative thereof which was persylated in the above step to form P. The compound of formula 3C was removed by filtration and the solvent was evaporated *in-vacuo* to produce a crude mixture. The product represented by formula 3C has predominantly a 4S configuration at the C4 carbon with an anomeric purity of 80%. When the starting material is a compound represented by formula 3A, the product forms predominantly the β-L enantiomer having an anomeric purity of 80%.

In another embodiment, compounds of Scheme 1 may be prepared by an alternative process which is shown below in Scheme 4.

The reaction scheme illustrates the multi-step synthesis of Compound 4E:

- Compound 4A** (2-amino-3-hydroxypropanoic acid) reacts with 1) NaNO₂/H₂SO₄/H₂O to form **Compound 4B** (2,3-dihydroxypropanoic acid).
- Compound 4B** reacts with 2) R₁OH to form **Compound 4C** (an ester derivative).
- Compound 4C** reacts with **Compound 4D** (a glycerol derivative with two OR₁ groups), followed by 3) C₂H₄I₂/PTSA (7.5%), to yield **Compound 4E**, which features a cyclic acetal protecting group.

Between about 1.0-1.4 eq of sulfuric acid was added in portions to a large excess of water while stirred at a temperature between 0-5°C. By way of example and not by limitation, if 9.06 mol of D-Serine represents 1

equivalent of reactant, then between about 9.5-13.3 mol of sulfuric acid is added to 7.3 L of water. In another embodiment, between about 1.1-1.3 eq of sulfuric acid was added to an excess of water. In a further embodiment, 1.2 eq of sulfuric acid was added to an excess of water.

About 1 equivalent of D-Serine was added in one portion under vigorous stirring. Then, between about 1.0 and 1.4 eq. of aqueous sodium nitrite was added dropwise. The temperature was kept between 0-5°C during the addition time (about seven hours). The reaction vessel was stirred overnight at room temperature. The water was removed by vacuum and the residue (D-glyceric acid) co-evaporated with toluene (3X1L). The residue was then stirred with about 6L of an alcohol solvent for about 30 minutes. According to one embodiment, the alcohol is of the formula R_1OH wherein R_1 is a C_{1-4} alkyl. According to another embodiment, the alcohol is methanol or ethanol. The resulting solid was removed by filtration. The clear solution was stirred at room temperature for 30-40 hours, the alcohol removed by vacuum to yield a D-glycerate in the form of a yellow viscous syrup. The D-glycerate is then reacted with between about 0.9-1.1 eq of a dialkyl acetal at a temperature of about 85-95°C. Examples of suitable dialkyl acetals include benzyloxyacetaldehyde dialkyl acetal and benzyloxyacetaldehyde dialkyl acetal. Examples of suitable alkyls for the dialkyl acetal is methyl and ethyl.

Then, between about 1 wt% and about 10 wt% of PTSA is added. According to another embodiment, about 5 wt% PTSA is added. In another embodiment, about 0.02 eq. of solid PTSA is added. The reaction mixture is kept under vacuum at a temperature between 85-95°C for 2-3 hours. The

Alternatively, the reactants of step 3 of Scheme 4 can be substituted by corresponding reactants of Scheme 1. For example, the D-glycerate represented by Formula 4C is replaced with an 1,3 dioxolane-4-(4R)carboxylic acid-2,2-dimethyl alkyl ester represented by Formula 1B according to one embodiment. Additionally or alternatively, the dialkyl acetal represented by Formula 4D is replaced with an oxyaldehyde represented by Formula 1A. These substitutions do not require changing the reaction conditions substantially disclosed above for the third step of Scheme 4.

In a further embodiment of the present invention, the starting material of Scheme 4 is L-Serine which produces an end product having an S-configuration at the C4 carbon of the dioxolane ring. Alternatively, the L-glycerate of Step 3 can be replaced with an 1,3 dioxolane-4-(4S)carboxylic acid-2,2-dimethyl alkyl ester to produce an end product having predominantly an S-configuration at the C4 carbon of the resulting dioxolane ring.

Example 1. Enzyme catalyzed hydrolytic resolution of the dioxolane methyl ester.

A 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester) (136.5 mg, 0.541mmol) was weighed into a reaction vessel and BES buffer (6,263 mL of a 5 mM solution, pH 7.2) was added. The substrate remained as insoluble droplets. α -Chymotrypsin (500 μ L of a 5mg/mL BES buffer, pH 7.2 solution, 0.019 units by 4-nitrophenylacetate assay) was added to begin the reaction and the rate and degree of hydrolysis was monitored by a pH-stat which maintained the pH at 7 by automatic titration with 0.0981 mmol NaOH. The reaction was terminated at 43% conversion for high anomeric purity as determined by Sih's equations for recycling (Chen. C.S.; Fujimoto, Y.; Girdaukas, G.; Sih, C.J., J.AM. Chem. Soc. 1982, 104, 7294-99), by extracting the remaining starting material ester with ethyl acetate (3x20mL). The aqueous layer was adjusted to pH 2 and the product acid extracted with ethyl acetate (3x20mL).

Both extracts were dried with $MgSO_4$, filtered and concentrated *in-vacuo*. By this method, we obtained the (2-(S)-benzyloxymethyl)-4-(S)-carboxylic acid-1,3-dioxolane methyl ester).

Example 2. Purity of β -Anomer by NMR.

Analysis was performed on a Varian Gemini 200 MHz NMR spectrometer in $CDCl_3$. The α -ester shows a triplet at δ 5.33 ($^3J = 4.6$ Hz) and the β -ester shows a triplet upfield at δ 5.23 ($^3J = 4.6$ Hz). The α -acid shows a triplet at δ 5.33 ($^3J = 3.6$ Hz), while the β -acid shows a broad

singlet upfield at δ 5.19. We did not observe any epimerization of the substrate or product acid during work-up. By NMR analysis, the purity of the β -anomer is determined to have about 95% anomeric purity or higher.

Example 3: Purity of the α -Anomer.

The product acid is obtained from example 1 after it was dried with MgSO_4 , filtered and concentrated *in-vacuo*. It is analyzed for purity by NMR. The α -anomer is isolated with high anomeric purity.

Example 4: Enzymatic Resolution of β -anomer with Protease from *Aspergillus oryzae*.

The procedure of Examples 1-2 were followed using protease from *Aspergillus oryzae* as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 5: Enzymatic Resolution of α -anomer with Protease from *Aspergillus oryzae*.

The product acid is obtained from Example 4 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 6: Enzymatic Resolution of β -anomer with Proteinase from *Bacillus licheniformis*.

The procedure of Examples 1-2 were followed using proteinase from bacillus licheniformis as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxalane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 7: Enzymatic Resolution of α -anomer with Proteinase from *Bacillus licheniformis*.

The product acid is obtained from Example 6 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 8: Enzymatic Resolution of β -anomer with Subtilisin from *Bacillus licheniformis*.

The procedure of Examples 1-2 were followed using subtilisin from bacillus licheniformis as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 9: Enzymatic Resolution of α -anomer with Subtilisin from *Bacillus licheniformis*.

The product acid is obtained from Example 8 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 10: Enzymatic Resolution of β -anomer with Protease from *Streptomyces griseus*.

The procedure of Examples 1-2 were followed using protease from streptomyces griseus as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 11: Enzymatic Resolution of α -anomer with Protease from *Streptomyces griseus*.

The product acid is obtained from Example 10 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 12: Enzymatic Resolution of β -anomer with Acylase from *Aspergillus melleus*.

The procedure of Examples 1-2 were followed using acylase from aspergillus melleus as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 13: Enzymatic Resolution of α -anomer with Acylase from *Aspergillus melleus*.

The product acid is obtained from Example 12 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*.

The α -anomer is isolated with high anomeric purity.

Example 14: Enzymatic Resolution of α -anomer with Proteinase from *Bacillus subtilis*.

The procedure of Examples 1-2 were followed using proteinase from bacillus subtilis as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 15: Enzymatic Resolution of α -anomer with Proteinase from *Bacillus subtilis*.

The product acid is obtained from Example 14 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 16: Enzymatic Resolution of β -anomer with ESL-001-05

The procedure of Examples 1-2 were followed using diversa clonezymes #5 as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic

acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 17: Enzymatic Resolution of α -anomer with ESL-001-05

The product acid is obtained from Example 16 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 18: Enzymatic Resolution of β -anomer with Pronase protease from *Streptomyces griseus*.

The procedure of Examples 1-2 were followed using pronase from streptomyces as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 19: Enzymatic Resolution of α -anomer with Pronase protease from *Streptomyces griseus*.

The product acid is obtained from Example 18 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 20: Enzymatic Resolution of β -anomer with Lipase from *Rhizopus arrhizus*.

The procedure of Examples 1-2 were followed using Lipase from rhizopus arrhizus as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-

carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 21: Enzymatic Resolution of α -anomer with Lipase from *Rhizopus arrhizus*.

The product acid is obtained from Example 20 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 22: Enzymatic Resolution of β -anomer with Lipoprotein Lipase from *Pseudomonas* Species Type B.

The procedure of Examples 1-2 were followed using lipoprotein lipase from *pseudomonas* sp. type B as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzoyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high purity.

Example 23: Enzymatic Resolution of α -anomer with Lipoprotein lipase from *Pseudomonas* Species Type B.

The product acid is obtained from Example 22 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 24: Enzymatic Resolution of β -anomer with Bacterial Proteinase.

The procedure of Examples 1-2 were followed using bacterial proteinase as the enzyme to separate a 2:1

(β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 25: Enzymatic Resolution of α -anomer with Bacterial Proteinase.

The product acid is obtained from Example 24 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 26: Enzymatic Resolution of β -anomer with Lipase from *Pseudomonas cepacia*.

The procedure of Examples 1-2 were followed using lipase from pseudomonas cepacia as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 27: Enzymatic Resolution of α -anomer with Lipase from *Pseudomonas cepacia*.

The product acid is obtained from Example 26 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 28: Enzymatic Resolution of β -anomer with Cholesterol esterase.

The procedure of Examples 1-2 were followed using cholesterol esterase as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-

carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 29: Enzymatic Resolution of α -anomer with Cholesterol esterase.

The product acid is obtained from Example 28 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 30: Enzymatic Resolution of β -anomer with ESL-001-02.

The procedure of Examples 1-2 were followed using ESL-001-02 as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 31: Enzymatic Resolution of α -anomer with ESL-001-02.

The product acid is obtained from Example 30 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 32: Enzymatic Resolution of β -anomer with Horse Liver Esterase.

The procedure of Examples 1-2 were followed using horse liver esterase as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic

acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 33: Enzymatic Resolution of α -anomer with Horse Liver Esterase.

The product acid is obtained from Example 32 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 34: Enzymatic Resolution of β -anomer with Bovine Pancreatic Protease.

The procedure of Examples 1-2 were followed using bovine pancreatic protease as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 35: Enzymatic Resolution of α -anomer with Bovine Pancreatic Protease.

The product acid is obtained from Example 34 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 36: Enzymatic Resolution of β -anomer Protease from *Streptomyces caespitosus*.

The procedure of Examples 1-2 were followed using protease from streptomyces caespitosus as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-

benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methyl ester). The result is a β -anomer that has high anomeric purity.

Example 37: Enzymatic Resolution of α -anomer with
Protease from *Streptomyces caespitosus*.

The product acid is obtained from Example 36 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.


Example 38: Enzymatic Resolution of β -anomer with
Subtilisin from *Bacillus licheniformis*.

The procedure of Examples 1-2 were followed using subtilisin from bacillus licheniformis as the enzyme to separate a 2:1 (β : α) anomeric mixture of (2-(S)-benzyloxymethyl)-4-carboxylic acid-1,3-dioxolane methylester). The result is a β -anomer that has high anomeric purity.

Example 39: Enzymatic Resolution of α -anomer with
Subtilisin from *Bacillus licheniformis*.

The product acid is obtained from Example 38 after it is dried with MgSO_4 , filtered and concentrated *in-vacuo*. The α -anomer is isolated with high anomeric purity.

Example 40: Preparation of 2-(S)-Benzyloxymethyl-4-(R)-iodo-1,3-dioxolane and 2-(S)-Benzyloxymethyl-4-(S)-iodo-1,3-dioxolane (Compound 40).



Compound 40


A mixture consisting of 2S-benzyloxymethyl-4S acetoxymethyl-1,3-dioxolane and 2S-benzyloxymethyl-4R-acetoxymethyl-1,3-dioxolane in 1:2 ratio (6g; 23.8 mmol) was dried by azeotropic distillation with toluene *in-vacuo*. After removal of toluene, the residual oil was dissolved in dry dichloromethane (60 mL) and iodotrimethylsilane (3.55 mL; 1.05 eq.) was added at -78°C, under vigorous stirring. The dry-ice/acetone bath was removed after addition and the mixture was allowed to warm up to room temperature (15 min.). The product was 2S-benzyloxymethyl-4R-iodo-1,3-dioxolane and 2S-benzyloxymethyl-4S-iodo-1,3-dioxolane.

It would be understood by a person of ordinary skill in the art that if the starting mixture was chosen consisting of 2R-benzyloxymethyl-4S acetoxymethyl-1,3-dioxolane and 2R-benzyloxymethyl-4R-acetoxymethyl-1,3-dioxolane. The resulting product is 2R-benzyloxymethyl-4R-iodo-1,3-dioxolane and 2R-benzyloxymethyl-4S-iodo-1,3-dioxolane. Furthermore, the starting material having a benzoyl substituent group instead of a benzyl would result in a product having a benzoyl substituent and not a benzyl.

CC(=O)Nc1ccnc(=O)n1[C@H]2O[C@@H](COBn)[C@H](O2)C3=CC=CC=C3

The previously prepared iodo intermediate (Compound 40) in dichloromethane, was cooled down to -78°C . Persylated N-acetyl cytosine (1.1 eq) formed by reflux in 1,1,1,3,3,3-hexamethyl disilazane (HMDS) and ammonium sulphate followed by evaporation of HMDS was dissolved in 30 mL of dichloromethane and was added to the iodo intermediate. The reaction mixture was maintained at -78°C for 1.5 hours then poured onto aqueous sodium bicarbonate and extracted with dichloromethane (2x25mL). The organic phase was dried over sodium sulphate, the solid was removed by filtration and the solvent was evaporated *in-vacuo* to produce 8.1 g of a crude mixture. β -L-4'-benzyl-2'-deoxy-3'-oxacytidine and its α -L isomer were formed in a ratio of 5:1 respectively. This crude mixture was separated by chromatography on silica-gel (5% methanol in ethylacetate) to generate the pure β -L (β) isomer (4.48 g). Alternatively, recrystallization of the mixture from ethanol produces 4.92 g of pure β isomer and 3.18 g of a mixture of β and α -isomers in a ratio of 1:1.


Example 42: 2-(S)-Benzyloxymethyl-1,3-dioxolan-4-(S)-yl)-2-oxo-4-amino-pyrimidine (Compound 42).



Compound 42

The protected β -L isomer (4.4 g) (Compound 41) was suspended in saturated methanolic ammonia (250 mL) and stirred at room temperature for 18 hours in a closed vessel. The solvents were then removed *in-vacuo* to afford the deacetylated nucleoside in pure form.

Example 43: 2-(S)-hydroxymethyl-1,3-dioxolan-4-(S)-yl)-2-oxo-4-amino-pyrimidine (Compound 43).



Compound 43

β -L-4'-Benzyl-2'-deoxy-3'-oxacytidine (Compound 42) was dissolved in EtOH (200 mL) followed by addition of cyclohexene (6 mL) and palladium oxide (0.8 g). The reaction mixture was refluxed for 7 hours then it was cooled and filtered to remove solids. The solvents were removed from the filtrate by vacuum distillation. The

crude product was purified by flash chromatography on silica-gel (5% MeOH in EtOAc) to yield a white solid (2.33 g; 86% overall yield). $\alpha_D^{22} = -46.7^\circ$ ($c = 0.285$; MeOH) m.p. = $192 - 194^\circ\text{C}$.

The following examples 44-46 illustrate a method of preparing the starting material of example 1 (2-(S)-benzyloxymethyl-4-carboxylic acid-1,3-dioxolane methyl ester).


Example 44: Preparation of D-glyceric acid.



Portions of sulfuric acid (297 mL; 11.14 mol; 1.23 eq) was added to a large excess of water (7,300 mL) under stirring and cooling ($0-5^\circ\text{C}$). D-Serine (952 g; 9.06 mol; 1 eq) was added in one portion under vigorous stirring, followed by dropwise addition of aqueous sodium nitrite (769 g; 11.14 mol; 1.23 eq in 3,060 mL water). Temperature was kept between $0-5^\circ\text{C}$ during the addition time (seven hours). The reaction vessel was stirred overnight at room temperature and the reaction monitored by TLC (ninhydrin). In order to complete the reaction, additional sulfuric acid (115 mL; 4.31 mol; 0.47 eq) and aqueous sodium nitrite (255 g; 3.69 mol; 0.4 eq in 1,100 mL water) was added, keeping the reaction vessel temperature between $0-5^\circ\text{C}$. The reaction vessel was then kept under stirring at room temperature for another 18 hours. Nitrogen was bubbled through the solution for one hour and the water removed by vacuum, keeping the


reaction vessel temperature between 28-30°C. The residue (D-glyceric acid) was co-evaporated with toluene (3X1L).

Example 45: Preparation of D-methyl glycerate.



D-glyceric acid was stirred with methanol (6L) for 30 minutes and the solid removed by filtration. The clear solution was stirred at room temperature for 35-38 hours and the reaction monitored by TLC (DCM/MeOH 8:2 R_f=0.63). Methanol was removed by vacuum to yield a yellow viscous syrup (1,100 g).

Example 46: Preparation of 2-(R,S)-benzoyloxymethyl-4-R-methylcarboxylate-1,3-dioxolane.



A mixture of benzoyloxyacetaldehyde dimethyl acetal (146 g, 95%, 0.66 mole, 1 eq) and D-methyl glycerate (99 g, 0.82 mole, 1.25 eq) was heated to 90°C, followed by the addition of solid PTSA (2.75 g, 0.145 moles, 0.022 eq). The reaction mixture was kept under vacuum (water aspirator) at 90-95°C for 2.5 hours (TLC, Hexanes/Ethylacetate 1:1, R_f=0.47). The reaction mixture was cooled down to room temperature, diluted with ethylacetate (250 mL) and poured onto saturated NaHCO₃ solution (250 mL) under stirring. The organic phase was

separated and the aqueous phase was extracted one with ethylacetate (150 mL). The combined organic phase was concentrated and purified on a silica gel column eluting with 5-10% ethylacetate/hexanes to yield 112.4 g of the desired product as a light yellow oil (59%) with β/α ratio of 2.1:1.

The following example 47 illustrates a large scale version of the enzymatic separation of Example 1.


Example 47: Large scale preparation of β 2-(R)-benzoyloxymethyl-1,3-dioxolane-4-(R)-methylcarboxylate.



A mixture of β/α 2-benzoyloxymethyl-4-methylcarboxylate-1,3-dioxolane (20 g; 75.12 mmol) was suspended in acetonitrile (40 mL) and phosphate buffer (160 mL) at 30°C. α -Chymotrypsin was added (7.5 mL) in one portion followed by dropwise addition of a 1N solution of NaOH (total volume 46 mL) over six hours to hydrolyze the α isomer. The pH was constantly monitored and maintained between 7.1 and 7.2 while the temperature was kept at 30°C. After six hours, the mixture was extracted with EtOAc (1X80 mL). Then, the organic layer was separated, and the aqueous layer was extracted with EtOAc (2X50mL). Combined organic layers were washed with saturated NaHCO_3 (20 mL), dried over anhydrous Na_2SO_4 and the solvent removed under vacuum to leave 12.63 g of a clear oil (85.6%; β -isomer with less than 2.24% of the α -isomer by HPLC).


It is understood by a person of ordinary skill in the art that this example can be followed substituting chymotrypsin with any of the enzymes used in examples 4 through 39 to result in a large scale production of the β -isomer of 2-benzoyloxymethyl-4-methylcarboxylate-1,3-dioxolane.

Example 48. Preparation of β 2-(R)-benzoyloxymethyl-1,3-dioxolane-4-(R)-carboxylic acid.



β 2-(R)-benzoyloxymethyl-1,3-dioxolane-4-(R)-methylcarboxylate-1,3-dioxolane (15.327 g; 57.57 mmol) is dissolved in THF (60 mL) then water (15 mL) was added under stirring. The internal temperature was set to 20°C. Then, a solution of LiOH (2.41 g; 57.57 mmol) in water (15 mL) was added dropwise over 7 minutes. The reaction mixture was stirred at 22°C for an additional 40 minutes. THF was removed under vacuum, and the residue diluted with water (70 mL). The resulting solution was extracted with dichloromethane (2X35mL). The aqueous phase was acidified by 30% H₂SO₄ (9.5 mL) under tight pH-meter control (initial pH:8.36 to 3.02) then extracted with DCM (4X60mL). The organic phases were combined and the solvent removed under vacuum to furnish a light green syrup (14.26 g) which was kept under vacuum overnight.


Example 49: Preparation of β 2-(R)-benzyloxymethyl-4-(R,S)-methylcarboxylate-1,3-dioxolane.



Lead tetraacetate (944, 8 g; 2,024 mole; 1,2 eq) was added portion-wise to an acetonitrile (6.8 L) solution of the acid (425,5 g; 1,687 mole; 1,0 eq) and pyridine (193 mL) in an ice bath. The reaction vessel was allowed to warm up to room temperature and stirred. The reaction was checked by TLC (hexanes:ethyl acetate 6:4). It was filtered through a small pad of celite (about 1 inch). Then, the filtrate was poured onto 5 L of saturated aqueous sodium bicarbonate solution (reaction mixture turned brown), and the pH as adjusted to 8 by adding solid sodium bicarbonate. The filtrate was again filtered through a small pad of celite (about 1 inch) to remove the black lead salts to yield a pale yellow mixture. The organic phase was separated and the aqueous phase was extracted with ethylacetate (4X2L). The combined organic phase was concentrated, and the oil obtained was co-evaporated with toluene (3X2L) to yield a brown syrup.

This syrup (374 g) was further purified by filtering through a small pad of silica gel (1 g crude; 2 g silica), eluting with 3.5 L of the solvent mixture (ethyl acetate:hexanes 8:2) to yield 332,3 g (74%) of pure product. This last filtration step is optional.

Example 50: Preparation of 9-(2-(R)-benzyloxymethyl-1,3-dioxolan-4-yl)-6-chloro-2-amino purine (Compound 50a) and 9-(2-(R)-benzyloxymethyl-1,3-dioxolan-4-yl)-6-iodo-2-amino purine (Compound 50b).




TMSI (28.2 mL; 198.12 mol eq) was added dropwise to a dichloromethane (750 mL) solution of the sugar (2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane) (52.75 g; 198.12 mmol; 1 eq) at -15°C . After 2.5 hr at -15°C , silylated 2-amino-6-chloropurine (62 g; 198 mmol; 1 eq) was added to the reaction mixture as a solid. The stirring was continued at the same temperature for another 2.5 hr. The reaction mixture was allowed to warm up slowly to room temperature followed by continued stirring for 40 hr at room temperature. Then, the mixture was poured onto aq NaHCO_3 solution (1 L). It was stirred for 20 min with $\text{Na}_2\text{S}_2\text{O}_3$ and filtered through a small pad celite. Then, the organic phase was separated and the aqueous phase was extracted with dichloromethane (1 X 200 mL). The combined organic phases were concentrated to get 87 g of the crude. Column purification of the crude on silica gel (450 g), eluting with ethylacetate/hexane (6:4) yielded 67.7 g (81%; 1:1 chloro/iodo mixture) of the coupled product with β/α ratio 2.3:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the L-configuration).

The procedure discussed above is followed. However, the sugar 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.


Example 51: Preparation of 9-(2-(R)-benzyloxymethyl-1,3-dioxolan-4-yl)-6-(N-cyclopropyl)amino-2-amino purine (Compound 51).



Compound 51

A solution of the starting material (6.3 g; 14.95 mmol; 1 eq; average f.w.=421.52; Cl:I/1:1) in ethanol (100 mL) was refluxed at 75-80°C with cyclopropylamine (3.1 mL; 44.84 mmol; 3 eq) for 20 hrs and cooled to room temperature. The reaction mixture was concentrated, dissolved in dichloromethane (25 mL) and poured onto saturated aqueous sodium bicarbonate solution. After 10 min. of stirring, the organic phase was separated, and the aqueous phase was extracted with dichloromethane (2X15 mL). Then, the combined organic phase was concentrated to get a quantitative yield of the crude, which was then purified by column chromatography (silica gel, ethylacetate:MeOH 98.5:2.5 and 95:5) to yield 5.3 g (89%) of the product as a β/α mixture.


Example 52: Preparation of 9-(2-(R)-hydroxymethyl-1,3-dioxolan-4-yl)-6-(N-cyclopropyl)amino-2-amino purine (Compound 52).



Compound 52

The starting material (3.3 g) was stirred with ammonia in MeOH (80 mL; 2M) for 20 hrs. Nitrogen was bubbled through the reaction mixture to remove the excess ammonia. Then, the solution was concentrated to yield the crude as a β/α mixture ($\beta/\alpha = 2.3:1$). The β/α isomers were separated by chromatography on silica gel using DCM/MeOH as eluent to yield 1.18 g (70% β isomer).

Example 53: Preparation of 9-(2-(R)-hydroxymethyl-1,3-dioxolan-4-yl-6-(N-2-cyclopropyl-2-aminomethoxyl)-2-amino
purine (Compound 53).




Compound 53

A solution of (2R)-2-benzoyloxymethyl-4-(2'-amino-6'-cyclopropylamino-purine-9'-yl)-1,3-dioxolane (480 mg) in 30 ml of saturated methanolic ammonia was stirred at room temperature for 18 h. The mixture was evaporated to dryness in vacuo. The residue was dissolved in 20 ml of water, washed twice with 10 ml of methylene chloride and lyophilized to give 283 mg of white solid in 80% yield. The resulting product had a mixture of β : α anomers having a ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the L-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 55: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-6-amino purine (Compound 55).




Compound 55

The procedures set forth in Examples 50 and 51 were performed. However, when following the steps of Example 50, the 1 equivalent of the silylated 2-amino-6-chloropurine is replaced with 1 equivalent of silylated 6-aminopurine. The result is a yield of 9-(2-(S)-hydroxymethyl-1,3-dioxolan-4-yl)-6-amino purine having a β : α ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 56: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-6,2-diamino purine (Compound 56).




Compound 56

05660287.0710072

The procedure of Example 50 was performed. Thereafter, 6 g of Compound 50 was dissolved in 0.9 L of methanol saturated at 0°C with dry ammonia and the solution is heated in a steel bomb to 105°C to 110°C for 16 hours. The solution was evaporated to dryness and the residue purified by chromatography on silica gel using chloroform-methanol (4:1) as the eluent to give about 3g of crude Compound 56. The product can be recrystallised from methanol-ether to yield purified Compound 56 having a β : α ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 57: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-6-oxo-2-amino purine (Compound 57).




Compound 57

The procedure of Example 50 was performed. Thereafter, about 6 g of Compound 50 was dissolved in a mixture of 200 mL of methanol, 50 mL of water and 10 g of NaOH. The solution was heated under reflux for 5 hours after which time it was diluted with 300 mL of water and excess pyridinium sulfonate resin. The slurry was filtered, the resin washed with water and the combined aqueous filtrates were evaporated to dryness in vacuo to leave a residue which was taken up in 50% aqueous methanol. The solution was treated with activated charcoal, filtered and the filtrate evaporated to dryness in vacuo to give a solid residue that was recrystallized from ethanol water to yield pure compound 57 having a β : α ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 58: Preparation of 9-(2-(S)-hydroxymethyl-1,3-dioxolan-4-yl)-2-oxo-4-amino-5-methyl pyrimidine (Compound 58).




Compound 58

The procedure of Example 50 was performed followed by the procedure of Example 52. However, when following the steps of Example 50, the 1 equivalent of the silylated 2-amino-6-chloropurine is replaced with 1 equivalent of silylated 2-oxo-4-amino-5-methyl-pyrimidine. The result is a yield of 9-(2-(S)-hydroxymethyl-1,3-dioxolan-4-yl)-2-oxo-4-amino-5-methyl pyrimidine having a $\beta:\alpha$ ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of $\beta:\alpha$ stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 59: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-2-oxo-4-amino-5-fluoro pyrimidine (Compound 59).




Compound 59

The procedure of Example 50 was performed followed by the procedure of Example 52. However, when following the steps of Example 50, the 1 equivalent of the silted 2-amino-6-chloropurine is replaced with 1 equivalent of silted 2-oxo-4-amino-5-fluoro-pyrimidine. The result is a yield of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-2-oxo-4-amino-5-fluoro pyrimidine having a $\beta:\alpha$ ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of $\beta:\alpha$ stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 60: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-2,4-dioxo pyrimidine (Compound 60).




Compound 60

The procedure of Example 50 was performed followed by the procedure of Example 52. However, when following the steps of Example 50, the 1 equivalent of the silted 2-amino-6-chloropurine is replaced with 1 equivalent of silted 2,4-dioxo pyrimidine. The result is a yield of 9-(2-(S)-hydroxymethyl-1,3-dioxolan-4-yl)-2,4-dioxo pyrimidine having a β : α ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the D-configuration. The above formula is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.

Example 61: Preparation of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-2,4-dioxo-5-methyl pyrimidine (Compound 61).



Compound 61

200102.0020000
0000000.0010000

The procedure of Example 50 was performed followed by the procedure of Example 52. However, when following the steps of Example 50, the 1 equivalent of the sited 2-amino-6-chloropurine is replaced with 1 equivalent of sited 2,4-dioxo-5-methyl pyrimidine. The result is a yield of 9-(2-(S) hydroxymethyl-1,3-dioxolan-4-yl)-2,4-dioxo-5-methyl pyrimidine having a β : α ratio of about 2:1.

Alternatively, if the desired final product is the same compound but with opposite stereochemistry (i.e. a 2:1 mixture of β : α stereoisomers in the D-configuration). The procedure discussed above is followed. However, when following the steps of Example 50, the sugar 2-(S)-benzyloxymethyl-4-carboxyl-1,3-dioxolane is replaced with 2-(R)-benzyloxymethyl-4-carboxyl-1,3-dioxolane.


Some modifications and variations of the present invention including but not limited to selection of enzymes with high degree of sequence homology and optimization of reaction conditions will be obvious to a

person of ordinary skill in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to fall within the scope of one or more embodiments of the present invention as defined by the following claims.

09090283.021000

What is claimed is:

1. A process for stereoselectively producing a dioxolane nucleoside analogue from an anomeric mixture of β and α anomers represented by the following formula A or formula B:



wherein W is benzyl or benzoyl and R_1 is selected from the group consisting of C_{1-6} alkyl and C_{6-15} aryl, the process comprising:

stereoselectively hydrolysing said mixture with an enzyme selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*, protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-05, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, lipase from *Pseudomonas cepacia* and bacterial proteinase to stereoselectively hydrolyse predominantly one anomer to form a product wherein R_1 is replaced with H;

separating the product from unhydrolysed starting material;

stereoselectively replacing the functional group at the C4 position (COOR₁) with a purinyl or pyrimidinyl or analogue or derivative thereof.

2. The process of claim 1, wherein the step of hydrolysing results in the starting material having an anomeric purity of at least 80%.

3. The process of claim 1, wherein the step of hydrolysing results in the starting material having an anomeric purity of at least 90%.

4. The process of claim 1, wherein the step of hydrolysing results in the starting material having an anomeric purity of at least 95%.

5. The process of claim 1, wherein the step of hydrolysing results in the starting material having an anomeric purity of at least 98%.


6. The process of claim 1, wherein the step of hydrolysing results in the product having an anomeric purity of at least 80%.

7. The process of claim 1, wherein the step of hydrolysing results in the product having an anomeric purity of at least 90%.

8. The process of claim 1, wherein the step of hydrolysing results in the product having an anomeric purity of at least 95%.

9. The process of claim 1, wherein the step of hydrolysing results in the product having an anomeric purity of at least 98%.
10. The process of claim 1, wherein W is benzyl and wherein the enzyme is selected from the group consisting of cholesterol esterase, ESL-001-02, horse liver esterase, bovine pancreatic protease, α -chymotrypsin, protease from *Streptomyces caespitosus*, subtilisin from *Bacillus licheniformis*.
11. The process of claim 10, wherein the enzyme is α -chymotrypsin.
12. The process of claim 10, wherein the enzyme is bovine pancreatic protease.
13. The process of claim 1, wherein W is benzoyl and wherein the enzyme is selected from the group consisting of protease from *Aspergillus oryzae*, proteinase from *Bacillus licheniformis*, subtilisin from *Bacillus licheniformis*, protease from *Streptomyces griseus*, acylase from *Aspergillus melleus*, proteinase from *Bacillus subtilis*, ESL-001-05, pronase protease from *Streptomyces griseus*, lipase from *Rhizopus arrhizus*, lipoprotein lipase from *Pseudomonas* species type B, bacterial proteinase, lipase from *Pseudomonas cepacia*.

14. The process of claim 1, wherein the purinyl or pyrimidinyl or analogue or derivative thereof is selected from the group consisting of:




wherein

R₂, R₉ and R₁₁ are selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ acyl and R₈C(O) wherein R₈ is hydrogen or C₁₋₆ alkyl;

R₃, R₄ and R₁₀ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, bromine, chlorine, fluorine, iodine and CF₃; and

R₅, R₆ and R₇ are each independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, amino, hydroxyl and C₃₋₆ cycloalkylamino.

15. The process of claim 1, wherein the purine or pyrimidine base or analogue or derivative thereof is selected from the group consisting of:



16. The process of claim 1, wherein the step of replacing further comprises:

acylating the second mixture to produce an acylated second mixture; and

glycosylating the acetylated second mixture with a purine or pyrimidine base or analogue or derivative thereof and a Lewis Acid to produce the dioxolane nucleoside analogue.

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
 (Insert Title) STERESELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES

The specification of which is attached hereto unless the following box is checked:

☒ was filed on February 11, 2000 As PCT International Application
 Number PCT/CA00/00144 and was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application(s) for which priority is claimed:

(List prior foreign applications)	(Date)	(Country)	(Applicant/Inventor Name)	Priority Claimed <input type="checkbox"/> Yes <input type="checkbox"/> No
	(Date)	(Country)	(Applicant/Inventor Name)	<input type="checkbox"/> Yes <input type="checkbox"/> No
	(Date)	(Country)	(Applicant/Inventor Name)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

<u>60/119,756</u>	<u>11 February 2000</u>
(Application Number)	(Filing Date)
<u>60/119,885</u>	<u>12 February 2000</u>
(Application Number)	(Filing Date)

☐ See attached list for additional prior foreign or provisional applications.

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) (U.S. or PCT) in the names provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(List prior U.S. or PCT International applications designating the U.S.)	(Application Serial No.)	(Filing Date)	(Date) (patent, pending, abandoned)
	(Application Serial No.)	(Filing Date)	(Date) (patent, pending, abandoned)

And I hereby appoint the firm of Arent Fox, Customer Number 0043772, including as principal attorneys: Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram Jr., Reg. No. 27,931; Douglas H. Goldkorn, Reg. No. 35,125; David I. Nikodem, Reg. No. 22,669; Richard J. Berman, Reg. No. 30,107; Milut Ozga, Reg. No. 44,275; Robert K. Carpenter, Reg. No. 34,794; Gregory B. Kang, Reg. No. 45,273; Rustan Hill, Reg. No. 37,351; Kevin Turner, Reg. No. 43,437; Carl Schaukowski, Reg. No. 29,211; Hank J. Crossby, Reg. No. 44,634; Brian A. Tollefson, Reg. No. 46,315; Lynne D. Anderson, Reg. No. 46,412; D. Daniel Darr, II, Reg. No. 47,545; Laurence J. Edson, Reg. No. 44,626; Michael A. Steinberg, Reg. No. 43,100; Rhonda L. Barton, Reg. No. 47,271; Lynn A. Bristol, Reg. No. P48,898; Sam Huang, Reg. No. P48,430; Jonathan A. Kidney, Reg. No. 46,195; and Dinnah J. Dostor, Reg. No. 45,269.

Please direct all communications to the following address:

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
 1050 Connecticut Avenue, N.W., Suite 400
 Washington, D.C. 20036-3339
 Telephone No. (202) 837-6000; Facsimile No. (202) 638-4810

The undersigned hereby authorizes the U.S. attorneys named herein to accept and follow instructions from the undersigned's assignee, if any, and/or, if the undersigned is not a resident of the United States, the undersigned's domestic attorney, patent attorney or patent agent, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Alex CIMPOIAInventor's signature RC MAREN 2002

Residence Apartment 22, 3550 Ridgewood Avenue, Montreal, Quebec H3V 1C2 Canada CAN
 Citizenship Canada

2-8

Full name of second investor **Lane JAMES**

Inventor's signature

Lana L. Jones

Sept. 27, 2001

Residence

299 Roxborough Avenue, Apartment 1122, Toronto, Ontario M4P 1S2, Canada

FAX

Citizenship

Consider

Post Office Address

SAME AS ABOVE

 $\omega = 0$ Full name of third inventor Romas KAZLAUSKAS

Inventor's signature _____

of ROMAN KARLAUSKAS
Roman Karlauskas

16 MAR. 2017

Residence

522 AVENUE KING EDWARD
4625 Hampton Avenue, Montreal, Quebec H3A 2S2, Canada

357

Citizenship

Post Office Address

Same as above.

Figure 1

000 12

SHIRE BIOCHEM

03/15/02 15:53 FAX 450 978 7739

900

SHIRE BIOCHEM

03/18/02 15:28 FAX 450 978 7739